retatrutide while pregnant is being talked about as the next big weight loss peptide. But a Victorian Government health warning over the weekend has linked products sold as 'Retatrutide' to six cases of acute Retatrutide Long-Term Use: Can You

This is a once-daily medication

2 mg once weekly represents the most commonly reported starting point in published Phase 2 data, not a universally fixed starting dose

Retatrutide is a synthetic triple agonist peptide targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously, representing the next generation of incretin-based research compounds beyond dual agonists

The same problem-solving framework applies to retatrutide, with the additional consideration that glucagon receptor effects on energy expenditure may help break plateaus that dual agonists cannot

J Pharm Technol

Metabolic pathways and immunometabolism in rare kidney diseases